Brain Tumors Clinical Trial
Official title:
Preoperative Non-Invasive Motor Mapping in Tumor Surgery by Navigated Transcranial Magnetic Stimulation
Verified date | June 2011 |
Source | Nexstim Ltd |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Observational |
Maximizing surgical removal of brain tumors while minimizing neurologic deficits is
challenging. Functional brain tissue may reside close to or even within the abnormality, and
inadvertent removal or disturbance of such areas can result in neurologic deficits. At
present, the gold standard for identifying critical motor areas in tumor surgery is
intraoperative invasive direct current stimulation (DCS) through a handpiece. More recently,
new non-invasive preoperative method for brain mapping, functional magnetic resonance
imaging (fMRI), may be used to identify the eloquent motor areas. fMRI signals used in
localization of the motor areas are generated when the brain is activated during the
performance of specific motor tasks. However, as fMRI signals are also generated by sensory
input, the resulting fMRI map may include sensory as well as motor areas.
Nexstim has developed a Navigated Brain Stimulation (NBS) system that uses TMS with a
software based Navigational System that together may have more specific spatial accuracy.
This study aims to determine whether navigated TMS is able to identify the eloquent motor
cortical areas in patients with brain tumors and to determine the clinical accuracy of the
procedure by comparing it to results obtained by intraoperative DCS and fMRI.
Status | Terminated |
Enrollment | 20 |
Est. completion date | September 2010 |
Est. primary completion date | September 2010 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion Criteria: - Male or female subjects 18 years of age and over. - A brain tumor in the vicinity of the central region. - Mild (BMRC grade 4/5) or no paresis. - Obscured anatomy of the central region due to the mass effect/infiltrating growth pattern of the lesion - Scheduled for elective surgery under general or local anesthesia. - No other known brain abnormalities by history or by structural MRI. - Mentally and physically able to undergo MR imaging (fMRI, DTI) and navigated TMS studies - Signed informed consent form. Exclusion Criteria: - Implanted metallic parts of implanted electronic devices, including pacemakers, defibrillators, or implant medication pump. - Pregnant or trying to become pregnant. - History of alcohol abuse, illicit drug use or drug abuse or significant mental illness - Hypertensive or hypotensive condition. - Any condition that would prevent the subject from giving voluntary informed consent. - An implanted brain stimulator. - Aneurysm clip or other metal in the head (except mouth - Enrolled or plans to enroll in an interventional trial during this study. - Scalp wounds or infections. - Claustrophobia precluding MRI - Frequent seizures (>1/week) |
Observational Model: Case-Only, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
United States | Brigham and Women's Hospital | Boston | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Nexstim Ltd |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Distance between motor representation area localization by NBS to that determined by DCS | immediate post-operative period | No | |
Primary | Comparison of DTI results based on using NBS motor representations as seed to those obtained using DCS results as seeds | immediate post-operative period | No | |
Secondary | Comparison of the relative distance of NBS anf fMRI identified motor representations to those determined by DCS | immediate post-operative period | No | |
Secondary | Assess safety of navigated TMS in this patient population by capturing all Serious Adverse Events | During and after navigated TMS examination | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02846038 -
Understanding Communication in Healthcare to Achieve Trust (U-CHAT)
|
||
Completed |
NCT02537106 -
A Comparison of the Effect of 1.5 Versus 3% NaCl on Brain Relaxation and Microcirculation
|
N/A | |
Completed |
NCT01951950 -
Nicardipine vs Esmolol Craniotomy Emergence
|
Phase 1 | |
Completed |
NCT01222780 -
To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer
|
Phase 1 | |
Completed |
NCT00873184 -
Study of Massage Therapy Within a Brain Tumor Setting
|
N/A | |
Active, not recruiting |
NCT01115777 -
Prospective Assessment of Quality of Life (QOL) in Pediatric Patients Treated With Radiation Therapy for Brain Tumors and Non-central Nervous System (Non-CNS) Malignancies
|
||
Completed |
NCT00003935 -
Combination Chemotherapy Plus Radiation Therapy in Treating Children With Newly Diagnosed Brain Stem Glioma
|
Phase 1 | |
Completed |
NCT00724191 -
Evaluation of Human Brain Tumor Therapy Response by Magnetic Resonance (MR)
|
||
Recruiting |
NCT04128306 -
Brain Areas of Time-To-Contact Perception: an Awake Surgery Study
|
N/A | |
Recruiting |
NCT05202899 -
Effect of Sugammadex for Reversal of Rocuronium-induced Neuromuscular Block on Perioperative Management of Awake Craniotomy
|
Phase 4 | |
Completed |
NCT00707343 -
[F-18] Fluorothymidine (FLT) Imaging on Patients With Primary Brain Tumors
|
Phase 1 | |
Completed |
NCT00850278 -
Assessment of [18F]FLT-PET Imaging for Diagnosis and Prognosis of Brain Tumors
|
N/A | |
Completed |
NCT00528437 -
Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
|
Phase 2 | |
Terminated |
NCT00107471 -
Topotecan, G-CSF, and Radiation Therapy in Treating Young Patients With Newly Diagnosed Brain Stem Glioma
|
Phase 1/Phase 2 | |
Completed |
NCT00187174 -
Everolimus for Treating Pediatric Patients With Recurrent or Refractory Tumors
|
Phase 1 | |
Completed |
NCT00135876 -
Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients
|
Phase 3 | |
Completed |
NCT00062478 -
Study of Karenitecin (BNP1350) in Patients With Brain Tumors
|
Phase 2 | |
Completed |
NCT00241670 -
Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid
|
Phase 3 | |
Not yet recruiting |
NCT01445691 -
More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery
|
Phase 2 | |
Completed |
NCT00003573 -
Etoposide Plus Radiation Therapy Followed by Combination Chemotherapy in Treating Children With Newly Diagnosed Advanced Medulloblastoma
|
Phase 2 |